KR101469306B1 - 다이사이클로아자알칸 유도체, 이의 제조 방법 및 의학적 용도 - Google Patents

다이사이클로아자알칸 유도체, 이의 제조 방법 및 의학적 용도 Download PDF

Info

Publication number
KR101469306B1
KR101469306B1 KR1020107018542A KR20107018542A KR101469306B1 KR 101469306 B1 KR101469306 B1 KR 101469306B1 KR 1020107018542 A KR1020107018542 A KR 1020107018542A KR 20107018542 A KR20107018542 A KR 20107018542A KR 101469306 B1 KR101469306 B1 KR 101469306B1
Authority
KR
South Korea
Prior art keywords
compound
cyclopenta
pyrrole
hexahydro
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107018542A
Other languages
English (en)
Korean (ko)
Other versions
KR20100103881A (ko
Inventor
펭 초 탕
지강 린
헤준 뤼
푸키앙 자오
리 리
팡롱 양
지안홍 푸
린 왕
구앙유안 쉔
동리앙 구안
Original Assignee
장쑤 한서 파마슈티칼 캄파니 리미티드
샹하이 헨그루이 파마수티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 200810004727 external-priority patent/CN101230059B/zh
Application filed by 장쑤 한서 파마슈티칼 캄파니 리미티드, 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 filed Critical 장쑤 한서 파마슈티칼 캄파니 리미티드
Publication of KR20100103881A publication Critical patent/KR20100103881A/ko
Application granted granted Critical
Publication of KR101469306B1 publication Critical patent/KR101469306B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
KR1020107018542A 2008-01-23 2008-05-20 다이사이클로아자알칸 유도체, 이의 제조 방법 및 의학적 용도 Expired - Fee Related KR101469306B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN 200810004727 CN101230059B (zh) 2007-01-23 2008-01-23 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
CN200810004727.1 2008-01-23

Publications (2)

Publication Number Publication Date
KR20100103881A KR20100103881A (ko) 2010-09-28
KR101469306B1 true KR101469306B1 (ko) 2014-12-04

Family

ID=40921930

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107018542A Expired - Fee Related KR101469306B1 (ko) 2008-01-23 2008-05-20 다이사이클로아자알칸 유도체, 이의 제조 방법 및 의학적 용도

Country Status (9)

Country Link
US (2) US8304411B2 (enExample)
EP (1) EP2246347B1 (enExample)
JP (1) JP5438028B2 (enExample)
KR (1) KR101469306B1 (enExample)
BR (1) BRPI0822143A2 (enExample)
CA (1) CA2712352C (enExample)
MX (1) MX2010008049A (enExample)
RU (1) RU2487866C2 (enExample)
WO (1) WO2009094866A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174007B (zh) * 2011-03-11 2013-06-12 成都博天化工有限责任公司 [2-(2-氰基-吡咯烷-1-基)-2-氧代-乙基]-氨基甲酸叔丁基酯的工业化制备方法
CN103415520B8 (zh) 2011-12-21 2017-04-05 江苏恒瑞医药股份有限公司 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用
WO2014000629A1 (zh) 2012-06-25 2014-01-03 广东东阳光药业有限公司 六氢并环戊二烯衍生物、其制备方法及其在医药上的应用
CN104030967B (zh) * 2013-03-05 2018-01-02 连云港恒运药业有限公司 一种dpp‑iv抑制剂的中间体、其制备方法和通过其制备dpp‑iv抑制剂的方法
US9540324B2 (en) 2013-09-26 2017-01-10 Luc Therapeutics, Inc. Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
US20170301620A1 (en) * 2016-04-15 2017-10-19 International Business Machines Corporation Structure and process for metal cap integration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028961A2 (en) * 2004-09-03 2006-03-16 Athersys, Inc. Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280028A (en) * 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
ES2136291T3 (es) * 1994-05-18 1999-11-16 Nisshin Flour Milling Co Derivados de pirimidina.
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2003002553A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
TW200401635A (en) * 2002-07-23 2004-02-01 Yamanouchi Pharma Co Ltd 2-Cyano-4-fluoropyrrolidine derivative or salt thereof
GB0307856D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
WO2004087142A1 (en) * 2003-04-04 2004-10-14 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
US7514571B2 (en) * 2004-02-27 2009-04-07 Kyorin Pharmaceutical Co., Ltd. Bicyclo derivative
FR2870538B1 (fr) * 2004-05-19 2006-07-14 Servier Lab Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1778688A1 (en) * 2004-07-22 2007-05-02 Glaxo Group Limited Antibacterial agents
WO2007029086A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
CN101050194B (zh) * 2006-04-05 2013-08-21 上海恒瑞医药有限公司 双环辛烷类衍生物、其制备方法及其在医药上的用途
CN101230058A (zh) 2007-01-23 2008-07-30 上海恒瑞医药有限公司 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
CN101230059B (zh) 2007-01-23 2011-08-17 上海恒瑞医药有限公司 双环氮杂烷类衍生物、其制备方法及其在医药上的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028961A2 (en) * 2004-09-03 2006-03-16 Athersys, Inc. Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARLUENGA, JOSE et al., Chemistry- A European Journal, Vol. 3(8), 1997, pages 1324-1336. *
BARLUENGA, JOSE et al., Chemistry- A European Journal, Vol. 3(8), 1997, pages 1324-1336.*
MIHOVILOVIC, MARKO D. et al., ‘Application of dry-state adsorption condition (DSAC) Pauson-Khand cyclization for the synthesis of perhydrocyclopenta[c]pyrroles’, ARKIVOC, Vol.2(2), 2001, pages 28-33.*
MIHOVILOVIC, MARKO D. et al., 'Application of dry-state adsorption condition (DSAC) Pauson-Khand cyclization for the synthesis of perhydrocyclopenta[c]pyrroles', ARKIVOC, Vol.2(2), 2001, pages 28-33. *

Also Published As

Publication number Publication date
JP2011510026A (ja) 2011-03-31
RU2487866C2 (ru) 2013-07-20
WO2009094866A1 (en) 2009-08-06
US8415349B2 (en) 2013-04-09
CA2712352A1 (en) 2009-08-06
US8304411B2 (en) 2012-11-06
US20100311747A1 (en) 2010-12-09
JP5438028B2 (ja) 2014-03-12
EP2246347A1 (en) 2010-11-03
KR20100103881A (ko) 2010-09-28
RU2010128972A (ru) 2012-02-27
BRPI0822143A2 (pt) 2019-09-24
MX2010008049A (es) 2010-11-12
CA2712352C (en) 2016-05-10
AU2008349110A1 (en) 2009-08-06
EP2246347A4 (en) 2012-01-11
EP2246347B1 (en) 2016-09-28
US20130012705A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
KR101482159B1 (ko) 아자비시클로 옥탄 유도체, 이의 제조 방법 및 디펩티딜 펩티다아제 ⅳ의 저해제로서의 이의 용도
KR101469306B1 (ko) 다이사이클로아자알칸 유도체, 이의 제조 방법 및 의학적 용도
WO2004009544A1 (ja) 2-シアノ−４−フルオロピロリジン誘導体又はその塩
JP4329382B2 (ja) 医薬組成物
JP4329291B2 (ja) 含窒素五員環化合物
US20050070719A1 (en) Inhibitors of dipeptidyl peptidase iv
EP1919864A2 (en) Fap inhibitors
CN114057702A (zh) 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途
CN101230059B (zh) 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
KR100714585B1 (ko) 약학적인 활성 피롤리딘 유도체
WO1991018877A1 (en) Novel arylalkanoylamine derivative and drug containing the same
JP2002516858A (ja) Ｈｉｖインテグラーゼ阻害薬
KR100549884B1 (ko) 에이즈 치료용 피롤 유도체
HU222353B1 (hu) Az N-terminálison szulfonil- vagy szulfamoil-csoportokat tartalmazó dipeptid-(p-amido-benzil)-amidok és alkalmazásuk
WO2005073186A1 (ja) ピロリジン誘導体
KR100547193B1 (ko) 시아노-피라졸린 유도체와 이의 약학적으로 허용가능한 염및 이의 제조 방법
HK1117164B (en) Dicyclic azaalkane derivatives, preparing method and pharmaceutical use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20171129

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20171129